China’s mRNA COVID-19 Vaccine May Start Late-Stage Trial in May: State Media

April 13, 2021

(Reuters) – China’s locally developed COVID-19 vaccine candidate that uses messenger RNA (mRNA) technology could start late-stage clinical trial overseas as early as next month, official media said on Tuesday. ARCoV, the China-developed mRNA vaccine candidate that is furthest along the clinical trial process, may get overseas approval to conduct Phase III clinical trial by as early as end-April, China National Radio said in an article on its website.